Osimertinib for maintenance treatment of EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy [ID6223]

Draft guidance

Draft guidance (online commenting)

Draft guidance (downloadable version) (PDF 317 KB)

Committee papers - ACM1 (PDF 6.17 MB)

Public committee slides - ACM1 (PDF 624 KB)

Final scope (PDF 195 KB)

Final stakeholder list (PDF 167 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 382 KB)

Draft matrix post referral (PDF 167 KB)

Note

Note

Note

Note

Note